A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT BLIND, SINGLE ASCENDING DOSE, PLACEBO CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO6926496 FOLLOWING INTRAVENOUS INFUSION IN HEALTHY SUBJECTS
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2016
At a glance
- Drugs RG 7345 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Roche
- 31 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2015 Planned End Date changed from 1 Nov 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov record.